Wire · opportunities
BridgeBio Shifts BBO-8520 Focus to KRAS Combinations in Second-Line NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
BridgeBio Oncology Therapeutics is shifting its BBO-8520 drug development focus to combination therapies targeting KRASG12C-mutant non-small cell lung cancer (NSCLC) in the second-line or later setting, leveraging promising monotherapy Phase 1 data and Fast Track FDA designation to potentially speed development.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your KRAS-targeting cancer therapy now needs combination data to compete in NSCLC second-line treatment. Fast Track FDA status opens an accelerated path if your combos outperform current therapies, so focus on generating compelling combination results quickly.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics